VRtech Düsseldorf medtech company CUREOSITY has raised a further €3.8 million, bringing the company’s funding to over €8.4 million.
The company develops therapy based on virtual reality and gamification, combining neuroscientific findings, in particular the potential of neuroplasticity, with many years of therapy experience.
The 50 trainings in 7 modules can be used in physiotherapy, occupational therapy, and neuropsychology across all phases and regardless of location and are aimed at people with sensorimotor, cognitive and perceptual impairments.
Since the market launch of the VR therapy CUREO®, the SaaS company has grown strongly and is now in use in almost 200 therapeutic facilities across 24 countries.
According to Caesar van Heyningen, CEO:
"The idea for the CUREO® therapy software arose from a personal need of the three founders, and a successful course — consisting of scaling markets and high-quality updates of our therapy software — is strengthened by this financing.
We plan to invest heavily in commercial expansion, incorporating tomorrow's technological possibilities into our product roadmap today. With this financing round, we can ensure financial independence and sustainable business operations. A privilege — especially in tight market conditions."
Investors include TechVision Fund (TVF) and the Belgian family office Nomainvest.
According to Björn Lang, Partner at TVF:
"CUREOSITY solves the problem of the shortage of skilled workers in the field of therapy. Especially due to demographic change, smart solutions like CUREO® are highly relevant to society."
The additional capital will be used, among other things, to further expand CUREO®'s market leadership in the field of VR therapy.
Lead image: Caesar van Heyningen (CEO), Thomas Saur (CVO), and Stefan Arand (CTO) of CUREOSITY. Photo: uncredited.
Would you like to write the first comment?
Login to post comments